<DOC>
	<DOC>NCT00299377</DOC>
	<brief_summary>Randomized comparison of abciximab i.v. versus i.c. in patients with STEMI undergoing primary PCI. The hypothesis is, that higher concentration of abciximab i.c. leads to improved epicardial flow, perfusion, reduction of no-reflow, reduction in infarct size and subsequently better outcome.</brief_summary>
	<brief_title>Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1. Clinical symptoms: Angina &lt; 12 h persistent Angina &gt; 30 min. 2. ECGCriteria: STelevation &gt; 1mm in ≥ 2 extremity leads STelevation &gt; 2mm in ≥ 2 contiguous anterior leads 3. Informed consent 1. No consent 2. Pregnancy 3. Allergy against abciximab, ASA or heparin 4. Active peptic ulcus ventriculi or duodeni 5. Active nonsuperficial bleeding 6. Major surgical intervention, intracerebral interventions, puncture central artery &lt; 4 weeks 7. Active internal bleeding 8. Cerebrovascular complications &lt; 2 years 9. Known coagulation disorders, thrombocytopenia 10. Arteriovenous malformations or aneurysms 11. Severe Liver or renal dysfunction 12. Severe untreated hypertension 13. Active vasculitis 14. Previous thrombolysis &lt; 12 h</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>STEMI</keyword>
	<keyword>infarct size</keyword>
	<keyword>primary PCI</keyword>
	<keyword>no-reflow</keyword>
	<keyword>ST-elevation myocardial infarction</keyword>
</DOC>